RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence.

"T. S. Hassan is a consultant for Alcon, Allergan, Aviceda, Bayer, Beaver-Visitrec International, Genentech, IVERIC bio, Katalyst, Novartis, Oculis, Oculus Surgical, Ocutrx, Regeneron, Roche, Surgicube, Vitreq, and Zeiss; has equity in Aviceda and Surgicube; and has patent royalties from Katalyst and Oculus Surgical. A. M. Khanani is a consultant for 4DMT, AbbVie, Adverum Biotechnologies, AGTC, Aldebaran Therapeutics, Alimera, Apellis, Arrowhead, AsclepiX Therapeutics, Aviceda, Bausch + Lomb, Broadwing Bio, Cholgene, EyePoint Pharmaceuticals, Frontera Therapeutics, Gemini, Genentech, Glaukos, Graybug Vision, Gyroscope Therapeutics, IVERIC bio, Janssen, Kartos Therapeutics, Kato Pharma, Kodiak Sciences, Kriya Therapeutics, Nanoscope, Novartis, Ocular Therapeutix, Oculis, OcuTerra, Opthea, Oxurion, Perfuse, PolyPhotonix, RecensMedical, Regeneron, REGENXBIO, Retrotope, RevOpsis, Roche, Stealth Biotherapeutics, Thea, Unity Biotechnology and Vanotech; receives research support from 4DMT, Adverum Biotechnologies, Alkahest, Annexon Biosciences, Apellis, AsclepiX Therapeutics, Gemini, Genentech, Graybug Vision, Gyroscope Therapeutics, IVERIC bio, Kodiak Sciences, Neurotech, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Oculis, Opthea, Oxurion, RecensMedical, REGENXBIO, Roche and Unity Biotechnology; has equity in Aviceda, PolyPhotonix, RecensMedical, and Retrotope; and is a speaker for AbbVie, Apellis, Bausch + Lomb, Genentech, and Novartis. J. S. Heier is a consultant for 4DMT, Abpro, Adverum Biotechnologies, Affamed, AGTC, Akuous, Allegro Ophthalmics, Allergan, Annexon Biosciences, Apellis, AsclepiX Therapeutics, Bionic Vision Technologies, Biovisics, Ciana, Curacle, DTx Pharma, Gemini, Genenetech, Graybug Vision, Gyroscope Therapeutics, IVERIC bio, Janssen R&D, Kriya Therapeutics, Nanoscope, NGM Biopharmaceuticals, Notal Vision, Novartis, OcuTerra, OliX, Palatin Technologies, Perceive Therapeutics, Regeneron, REGENXBIO, RetinAI, RevOpsis, Stealth Biotherapeutics, Thea, Unity Biotechnology, and Vanotech; receives research support from Annexon Biosciences, Apellis, AsclepiX Therapeutics, Bayer, Genentech/Roche, Gyroscope Therapeutics, IVERIC bio, jCyte, Kodiak Sciences, NGM Biopharmaceuticals, Notal Vision, Regeneron, and REGENXBIO; and has equity in Adverum Biotechnologies, Aldeyra, Allegro Ophthalmics, Aviceda, DTx Pharma, jCyte, Ocular Therapeutix, RevOpsis, Vinci, and Vitranu."

"H. Matsumoto is funded by Japan Society for the Promotion of Science KAKENHI (grant number JP 21K09672) and has received personal compensation from Bayer (Japan), Novartis (Japan), Santen (Japan), and Senju (Japan). Support with development of this manuscript for publication was provided by Oxford PharmaGenesis, with the financial support of Novartis."